Overall, the findings imply that TM treatments protect against cerebral infarction at least partly by suppressing the interaction between JNK and TLR4 in microglia in the cortical ischemic rim 2 days after transient MCA occlusion. The gene discussed is TLR4; the disease is brain infarction.